MA37291A2 - Macrocyclic derivatives for the treatment of proliferative diseases - Google Patents
Macrocyclic derivatives for the treatment of proliferative diseasesInfo
- Publication number
- MA37291A2 MA37291A2 MA37291A MA37291A MA37291A2 MA 37291 A2 MA37291 A2 MA 37291A2 MA 37291 A MA37291 A MA 37291A MA 37291 A MA37291 A MA 37291A MA 37291 A2 MA37291 A2 MA 37291A2
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- compounds
- proliferative diseases
- salts
- macrocyclic derivatives
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 230000002062 proliferating effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 abstract 1
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne des composés de formule (¦) tels que définis dans la description et des sels pharmaceutiquement acceptables de ceux-ci. Elle concerne également des compositions pharmaceutiques comprenant de tels composés et sels et les utilisations de ceux-ci. Les composés et sels de la présente invention inhibent la kinase lymphome anaplasique (alk) et/ou l'eml 4-alk et sont utiles pour traiter ou améliorer des troubles de la prolifération cellulaire anormale, tels que le cancer.The invention relates to compounds of formula (I) as defined in the description and pharmaceutically acceptable salts thereof. It also relates to pharmaceutical compositions comprising such compounds and salts and uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (alk) and / or eml 4-alk and are useful for treating or ameliorating disorders of abnormal cell proliferation, such as cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261607485P | 2012-03-06 | 2012-03-06 | |
| PCT/IB2013/051391 WO2013132376A1 (en) | 2012-03-06 | 2013-02-20 | Macrocyclic derivatives for the treatment of proliferative diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| MA37291A2 true MA37291A2 (en) | 2016-10-31 |
| MA37291A3 MA37291A3 (en) | 2018-05-31 |
| MA37291B1 MA37291B1 (en) | 2019-01-31 |
Family
ID=55171500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37291A MA37291B1 (en) | 2012-03-06 | 2013-02-20 | Macrocyclic derivatives for the treatment of proliferative diseases |
Country Status (2)
| Country | Link |
|---|---|
| MA (1) | MA37291B1 (en) |
| UA (1) | UA110293C2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112321604A (en) * | 2019-08-05 | 2021-02-05 | 华东理工大学 | Macrocyclic JAK2 inhibitor and application thereof |
-
2013
- 2013-02-20 MA MA37291A patent/MA37291B1/en unknown
- 2013-02-20 UA UAA201408703A patent/UA110293C2/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112321604A (en) * | 2019-08-05 | 2021-02-05 | 华东理工大学 | Macrocyclic JAK2 inhibitor and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| MA37291B1 (en) | 2019-01-31 |
| UA110293C2 (en) | 2015-12-10 |
| MA37291A3 (en) | 2018-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA38391A1 (en) | Pyridinyl and triazolone pyridinyl derivatives of fusion | |
| MA47079B1 (en) | Amino-triazolopyidin compounds and their use to treat cancer | |
| MY169142A (en) | Macrocyclic derivatives for the treatment of proliferative diseases | |
| MA40111B1 (en) | Derivatives of tetrahydronaphthalene inhibiting mcl-1 protein | |
| MA45920A (en) | PYRIDOPYRIMIDINONE CDK2 / 4/6 INHIBITORS | |
| MA40225A (en) | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | |
| WO2019035863A8 (en) | Pyruvate kinase activators for use in treating blood disorders | |
| TN2014000420A1 (en) | INDOLE AND INDAZOLE DERIVATIVES THAT ACTIVATE MPK | |
| TN2014000537A1 (en) | 4- (AMINO-SUBSTITUTED) - NEW 7H-PYRROLO [2,3-D] PYRIMIDINES AS INHIBITORS OF LRRK2 | |
| MA32014B1 (en) | Concentrated compounds of pyridine, pyrimidine and triazine as a cell inhibitor | |
| MA45598B1 (en) | 24-hydroxy steroles substituted in position 11 for the treatment of diseases linked to the nmda receptor | |
| MA42410A (en) | OXYSTEROLS AND THEIR METHODS OF USE | |
| MA37891A1 (en) | Alcoxypyrazoles as activators of soluble guanylate cyclase | |
| AU2011297889A8 (en) | Pharmaceutically active compounds as Axl inhibitors | |
| MA37831B1 (en) | Azaindole derivatives acting as pi3k inhibitor | |
| MA37400B1 (en) | Heterocyclyl compounds as mek inhibitors | |
| MA30952B1 (en) | CYCLOPENTA [D] PYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASE AKT | |
| MA29795B1 (en) | INHIBITORS OF DIPEPTIDYL PEPTIDASE FOR THE TREATMENT OF DIABETES | |
| MA29713B1 (en) | DERIVATIVES OF TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE | |
| MA29377B1 (en) | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | |
| TN2016000188A1 (en) | 2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | |
| CA2878796C (en) | Derivatives of pyridinone as inhibitors for tissue transglutaminase | |
| MA39165A1 (en) | Benzimidazole-proline derivatives for their use in the treatment of crepuscular state syndrome | |
| MA37291A2 (en) | Macrocyclic derivatives for the treatment of proliferative diseases | |
| TN2014000371A1 (en) | MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES |